{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:11:17Z","timestamp":1793797877122,"version":"4.6.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["ORF-2025-1103"],"award-info":[{"award-number":["ORF-2025-1103"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bioorg.2025.109278","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T21:55:06Z","timestamp":1763762106000},"page":"109278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Design, synthesis, and anticancer evaluation of spirooxindole\u20131,2,3-triazole hybrids as potent VEGFR-2 inhibitors"],"prefix":"10.1016","volume":"167","author":[{"given":"Assem","family":"Barakat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moayad Abdullah","family":"Alwehaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmajeed Abdullah","family":"Alayyaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhanna K.","family":"Al-Muhanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed W.","family":"Attwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessa H.","family":"Al-Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Nafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa M.","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Emara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2025.109278_bb0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109278_bb0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","article-title":"Angiogenesis in cancer","volume":"2","author":"Nishida","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109278_bb0015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00000658-197203000-00014","article-title":"Anti-angiogenesis: new concept for therapy of solid tumors","volume":"175","author":"Folkman","year":"1972","journal-title":"Ann. Surg."},{"issue":"7347","key":"10.1016\/j.bioorg.2025.109278_bb0020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109278_bb0025","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ctrv.2012.04.006","article-title":"Role of angiogenesis in the pathogenesis of cancer","volume":"38","author":"Hoff","year":"2012","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109278_bb0030","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1182\/blood-2012-01-406108","article-title":"CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis","volume":"120","author":"Jiang","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bioorg.2025.109278_bb0035","first-page":"123","article-title":"Clinical advances in the development of novel VEGFR2 inhibitors","volume":"2","author":"Fontanella","year":"2014","journal-title":"Ann Transl Med"},{"issue":"5","key":"10.1016\/j.bioorg.2025.109278_bb0040","first-page":"997","article-title":"Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation","volume":"34","author":"Liotta","year":"1974","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109278_bb0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109278_bb0050","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.109278_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117402","article-title":"A systematical comparison of anti-angiogenesis and anti-cancer efficacy of ramucirumab, apatinib, regorafenib and cabozantinib in zebrafish model","volume":"247","author":"Wu","year":"2020","journal-title":"Life Sci."},{"issue":"14","key":"10.1016\/j.bioorg.2025.109278_bb0060","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1021\/jm980123i","article-title":"Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases","volume":"41","author":"Sun","year":"1998","journal-title":"J. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2025.109278_bb0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbapap.2003.11.010","article-title":"Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis","volume":"1697","author":"Manley","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.bioorg.2025.109278_bb0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2005.09.033","article-title":"Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing","volume":"42","author":"Sessa","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"15","key":"10.1016\/j.bioorg.2025.109278_bb0075","first-page":"4152","article-title":"SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors","volume":"60","author":"Laird","year":"2000","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109278_bb0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S2468-1253(17)30290-X","article-title":"Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109278_bb0085","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2174\/0929867323666160210130426","article-title":"Anti-Angiogenic therapy: strategies to develop potent VEGFR-2 tyrosine kinase inhibitors and future Prospect","volume":"23","author":"Shi","year":"2016","journal-title":"Curr. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.109278_bb0090","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109278_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010244","article-title":"Resistance to MET\/VEGFR2 inhibition by Cabozantinib is mediated by YAP\/TBX5-dependent induction of FGFR1 in castration-resistant prostate Cancer","volume":"12","author":"Koinis","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109278_bb0100","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"Pt 1","key":"10.1016\/j.bioorg.2025.109278_bb0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/bj3510095","article-title":"Specificity and mechanism of action of some commonly used protein kinase inhibitors","volume":"351","author":"Davies","year":"2000","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109278_bb0110","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1476-5381.2012.01859.x","article-title":"A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets","volume":"166","author":"Uitdehaag","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109278_bb0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.bioorg.2025.109278_bb0120","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/molecules22060913","article-title":"Synthesis and evaluation of novel 2-Pyrrolidone-fused (2-Oxoindolin-3-ylidene)methylpyrrole derivatives as potential multi-target tyrosine kinase receptor inhibitors","volume":"22","author":"Yang","year":"2017","journal-title":"Molecules"},{"issue":"21","key":"10.1016\/j.bioorg.2025.109278_bb0125","doi-asserted-by":"crossref","first-page":"15858","DOI":"10.1021\/acs.jmedchem.1c01168","article-title":"Development of novel VEGFR2 inhibitors originating from natural product analogues with antiangiogenic impact","volume":"64","author":"Cho","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109278_bb0130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jconrel.2020.04.018","article-title":"Design principles of drug combinations for chemotherapy","volume":"323","author":"Wu","year":"2020","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.bioorg.2025.109278_bb0135","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1021\/acs.jmedchem.9b01269","article-title":"Discovery and characterization of 1H-1,2,3-Triazole derivatives as novel Prostanoid EP4 receptor antagonists for Cancer immunotherapy","volume":"63","author":"Yang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109278_bb0140","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1021\/jm401536b","article-title":"Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold","volume":"57","author":"Taddei","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109278_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111700","article-title":"1,2,3-Triazole-containing hybrids as potential anticancer agents: current developments, action mechanisms and structure-activity relationships","volume":"183","author":"Xu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109278_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.661173","article-title":"1,2,3-Triazole-containing compounds as anti-lung Cancer agents: current developments, mechanisms of action, and structure-activity relationship","volume":"12","author":"Liang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109278_bb0155","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1021\/acsomega.0c04595","article-title":"Design, synthesis, molecular modeling, anticancer studies, and density functional theory calculations of 4-(1,2,4-Triazol-3-ylsulfanylmethyl)-1,2,3-triazole derivatives","volume":"6","author":"Al Sheikh Ali","year":"2021","journal-title":"ACS Omega"},{"issue":"16","key":"10.1016\/j.bioorg.2025.109278_bb0160","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1016\/j.bmc.2019.07.005","article-title":"1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: a recent overview","volume":"27","author":"Bozorov","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109278_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113083","article-title":"Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold","volume":"211","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"28","key":"10.1016\/j.bioorg.2025.109278_bb0170","doi-asserted-by":"crossref","first-page":"22336","DOI":"10.1039\/D5RA03404C","article-title":"Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach","volume":"15","author":"Nafie","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109278_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2023.100903","article-title":"Efficient and environmentally friendly synthesis of 1,2,3-triazole derivatives via [3 + 2] cycloaddition and their potential as lung cancer inhibitors: an in silico study","volume":"5","author":"Boruah","year":"2023","journal-title":"Results Chem."},{"key":"10.1016\/j.bioorg.2025.109278_bb0180","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejmech.2015.08.017","article-title":"Spirooxindole-derived morpholine-fused-1,2,3-triazoles: design, synthesis, cytotoxicity and apoptosis inducing studies","volume":"102","author":"Senwar","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109278_bb0185","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ejmech.2016.09.009","article-title":"Synthesis and apoptosis inducing studies of triazole linked 3-benzylidene isatin derivatives","volume":"124","author":"Nagarsenkar","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109278_bb0190","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300185","article-title":"Synthesis and SARs study of novel spiro-oxindoles as potent antiproliferative agents with CDK-2 inhibitory activities","volume":"356","author":"Al-Jassas","year":"2023","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.bioorg.2025.109278_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2018.11.042","article-title":"Discovery of novel anti-angiogenesis agents. Part 10: multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol","volume":"163","author":"Pan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109278_bb0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.compbiolchem.2019.01.013","volume":"79","author":"Murugavel","year":"2019","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109278_bb0205","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.molstruc.2018.09.010","volume":"1176","author":"Murugavel","year":"2019","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109278_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2024.1460384","article-title":"Novel spirooxindole-triazole derivatives: unveiling [3+ 2] cycloaddition reactivity through molecular electron density theory and investigating their potential cytotoxicity against HepG2 and MDA-MB-231 cell lines","volume":"12","author":"Shawish","year":"2024","journal-title":"Front. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109278_bb0215","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1039\/D4RA05966B","article-title":"Potent EGFR\/PARP-1 inhibition by spirooxindole-triazole hybrids for targeted liver cancer therapy","volume":"15","author":"Nafie","year":"2025","journal-title":"RSC Adv."},{"issue":"19","key":"10.1016\/j.bioorg.2025.109278_bb0220","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.3390\/molecules28196976","article-title":"Synthesis and characterization of new spirooxindoles including Triazole and Benzimidazole pharmacophores via [3+ 2] cycloaddition reaction: an MEDT study of the mechanism and selectivity","volume":"28","author":"Alshahrani","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109278_bb0225","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13065-024-01343-8","article-title":"Utilizing MEDT analysis of [3+ 2] cycloaddition reaction: x-ray crystallography of spirooxindole linked with thiophene\/furan heterocycles and triazole framework","volume":"18","author":"Alayyaf","year":"2024","journal-title":"BMC Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.109278_bb0230","doi-asserted-by":"crossref","DOI":"10.1002\/ppap.202200234","article-title":"Treatment of hepatocellular carcinoma with in situ generated plasma-activated air-driven water mist","volume":"20","author":"Saadawy","year":"2023","journal-title":"Plasma Processes Polym."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109278_bb0235","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/cbdd.13997","article-title":"Quinoline-based thiazolidinone derivatives as potent cytotoxic and apoptosis-inducing agents through EGFR inhibition","volume":"99","author":"Nafie","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"issue":"28","key":"10.1016\/j.bioorg.2025.109278_bb0240","doi-asserted-by":"crossref","first-page":"24858","DOI":"10.1021\/acsomega.2c03079","article-title":"Synthesis and Antiproliferative activity of a new series of mono- and Bis(dimethylpyrazolyl)-s-triazine derivatives targeting EGFR\/PI3K\/AKT\/mTOR signaling cascades","volume":"7","author":"Shawish","year":"2022","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109278_bb0245","article-title":"In Vitro and in vivo studies of anti-lung cancer activity of artemesia judaica L. Crude extract combined with LC-MS\/MS metabolic profiling, docking simulation and HPLC-DAD quantification","volume":"11","author":"Goda","year":"2021","journal-title":"Antioxidants (Basel)"},{"issue":"11","key":"10.1016\/j.bioorg.2025.109278_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/ph15111334","article-title":"Comparative cytotoxic evaluation of Zygophyllum album root and aerial parts of different extracts and their biosynthesized silver nanoparticles on lung A549 and prostate PC-3 Cancer cell lines","volume":"15","author":"Abdelhameed","year":"2022","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825011587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825011587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:50:57Z","timestamp":1766123457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825011587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":50,"alternative-id":["S0045206825011587"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109278","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and anticancer evaluation of spirooxindole\u20131,2,3-triazole hybrids as potent VEGFR-2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109278"}}